Letermovir | Merck | ||
240, 480 mg ; Tablet |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
Less Than 5
|
||
None | None | ||
PREVYMIS is a CMV DNA terminase complex inhibitor indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). | |||
Yes
|
Prevymis | Patent 1 | Patent 2 |
---|---|---|
***** ****** | ******* **** **** | **** ** *** **, **** |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
***** ****** | *** \ ********* | *** **, **** | ******* | ********* ******** | *** ****** *** **** |